The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature
NCT ID: NCT01970800
Last Updated: 2018-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2013-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
NCT01438801
IGF1 Generation Test
NCT00145457
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
NCT05894876
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
NCT01734447
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
NCT00572156
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Growth hormone, injections
Growth hormone injection 0.3mg/kg/week dailY
Growth Hormone
Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Growth Hormone
Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prepubertal males and females form 5- 11years old
* Bone age \<11 years in males and \<9 years in females
* Height SD score\<-2.25SD in males and females
* IGF-1SD score \<-1SD in both males and females
* Peak GH level after stimulation \>10ng/ml
Exclusion Criteria
* Active neoplasm
* Pediatric patients with closed epiphyses
* Prader-Willi syndrome, Turner syndrome or any other genetic or chromosomal anomaly
* Treatment with inhaled or systemic steroids
* BMI \<5th percentile or \>95th percentile
* Tanner 2 at clinical or biochemical examination by ultrasensitive LH and FSH
5 Years
11 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maimonides Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Svetlana Ten, MD
Role: PRINCIPAL_INVESTIGATOR
Maimonides Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Maimonides Medical Center
Brooklyn, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10/01/VA03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.